Page 174 - Mployee Wellness Programs News Today

We need federal, state, and institutional leaders to invest in nurses earlier in the pipeline by increasing enrollment and program capacity and providing better resources like technology in the classroom so we can tackle the workforce shortage before it gets any worse.

It’s rare to find a clinician who raves about their organization’s EHR. A new KLAS report shed light on some of the key factors that contribute to clinicians' EHR dissatisfaction — including excessive alerts, downtime and inefficient training processes.

After three years of not having to renew Medicaid coverage, redeterminations are set to return April 1. Yet, more than 64% of enrollees are unaware. Constant repetition and outreach from healthcare players will be needed to combat this, one payer expert said.

GV led Chroma Medicines Series B financing round, which the biotech will apply toward epigenetic medicines that could offer advantages over other editing technologies. Other recent financings include rounds from Cargo Therapeutics and Transcend Therapeutics.

James Comer (R-Ky), House Committee on Oversight and Accountability chairman, sent letters to the Office of Personnel Management, Centers for Medicare and Medicaid Services and the Defense Health Agency asking for documents that show how PBMs’ practices are affecting federal government healthcare programs. In addition, he sent letters to CVS Caremark, Express Scripts and OptumRx, asking them to provide information on their tactics.

Aledade — an independent primary care network focused on value-based care — struck a 10-year partnership with insurer Humana. Under the collaboration, Humana’s Medicare Advantage members will receive primary care from Aledade physicians using value-based arrangements.

In the post-Roe environment of fear and uncertainty, femtech companies should actively review their data collection practices to ensure they are only collecting the minimum amount of data necessary for the app to function. Recent studies have shown that accurate women’s health predictions can be made by some companies that collect far less data than their competitors.

As regulatory processes and reimbursements are refined, there needs to be a continued focus on how to maximize the benefits for patients and ensure DTx can play a role in improving outcomes. The key to this is integration into the clinical workflow.

Cargo Therapeutics is developing CAR T-cell therapies that overcome ways cancers evade currently available treatments. True to its name, the startup’s approach involves putting more cargo and more complex cargo onto engineered T cells.

Eli Lilly is paying $40 million up front for rights to a Confo Therapeutics drug in Phase 1 testing as a potential treatment for neuropathic pain. Confo develops drugs that target G-protein coupled receptors.